Literature DB >> 34028879

The history, physiology and treatment safety of growth hormone.

Anders Tidblad1.   

Abstract

Growth hormone treatment was introduced in the 1950s to address growth disturbances and metabolic abnormalities. Hundreds of thousands of children have been treated, with gradual expansion of treatment indications. From initially being offered only to patients with severe growth hormone deficiency, today many children are treated for conditions in which the associated short stature is not primarily thought to be due to deficient endogenous growth hormone secretion. This review discusses the history, physiology and safety of growth hormone treatment, with focus on the long-term risks of mortality, cardiovascular morbidity and cancer.
Conclusion: Continuous follow-up is needed to increase our knowledge of the long-term treatment safety.
© 2021 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.

Entities:  

Keywords:  cancer; growth hormone treatment; long-term safety; physiology; risks

Mesh:

Substances:

Year:  2021        PMID: 34028879     DOI: 10.1111/apa.15948

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  2 in total

1.  Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.

Authors:  Aristides K Maniatis; Samuel J Casella; Ulhas M Nadgir; Paul L Hofman; Paul Saenger; Elena D Chertock; Elena M Aghajanova; Maria Korpal-Szczyrska; Elpis Vlachopapadopoulou; Oleg Malievskiy; Tetyana Chaychenko; Marco Cappa; Wenjie Song; Meng Mao; Per Holse Mygind; Alden R Smith; Steven D Chessler; Allison S Komirenko; Michael Beckert; Aimee D Shu; Paul S Thornton
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

2.  Association Between Recombinant Growth Hormone Therapy and All-Cause Mortality and Cancer Risk in Childhood: Systematic Review and Meta-Analysis.

Authors:  Mengyang He; Xiangling Deng; Xuan Wang; Yuxiang Wan; Jinchang Huang; Zhixin Zhang; Wenquan Niu
Journal:  Front Pediatr       Date:  2022-04-22       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.